tbuckley/cabot-search huggingface dataset:
The value of TOP2A as a target for anthracycline-based chemotherapy in advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology Group study.
Authors: Tatyana A. Grushko, Virginia L. Filiaci, Anthony G. Montag, Marsha A. Apushkin, Brandon Marzullo, Laura Monovich, Nilsa C. Ramirez, Michael J. Birrer, Olufunmilayo I. Olopade, Gini F. Fleming
Journal: Journal of Clinical Oncology (2015)

e16509 Background: Nuclear enzyme TOP2A controls the topologic states of DNA, and is a major target for anthracyclines. In the adjuvant trials of breast cancer, TOP2A is likely a marker of anthracycline sensitivity (NCIC CT MA.5, BCIRG-006). We aimed to investigate the expression and potential prognostic value of TOP2A in advanced or recurrent EC treated with anthracycline-based therapy. Methods: Specimens were available from 161 of 234 pts enrolled on a randomized GOG protocol 0177 testing the addition of paclitaxel to doxorubicin/cisplatin. IHC staining for TOP2A (KiS1) and HER2 (HercepTest) and HER2FISH (PathVysion) were evaluable in 155 ECs, and IHC for Ki67 (MIB1) in 120 cases. TOP2A expression was defined by ImmunoReactive Score (IRS: intensity x % stained cells score = combined score 0-12) as positive (TOP2A+; 4-12) or negative (TOP2A−; 0-3). Cox proportional hazard and logistic regression models were used to explore the relationship between TOP2A and outcome. Results: TOP2A+ expression was found in 48% (75 of 155) ECs. There was a significant association of TOP2A+ IRS with high grade (p = .03), high proliferation (Ki67, p = .003) and histology. The incidence of TOP2A positivity was higher among serous tumors (73%) vs all others (43%; p = .01). As to specimen type, when IRS was applied as a continuous variable, the association of TOP2A+ with recurrent/metastatic vs primary tissues was apparent with median score 6 vs 3 (p = .008), respectively. The association with FIGO stage was negative: stage III showed the highest proportion (71%) of TOP2A+ ECs vs stage IV (54%) or recurrent (41%; p = .01). TOP2A+ score was associated with HER2amplification (p = .007) but not with HER2 protein overexpression (p = .87). TOP2A+ expression was not associated with RR, PFS or OS with or without adjusting for treatment and performance status. Conclusions: TOP2A+ expression was more common in aggressive ECs and was associated with high proliferation. Our study does not show an association of TOP2A expression with prognosis in EC pts receiving anthracycline-containing therapy. Supported by NCI K12CA139160 and CTSA-ITM CS UL1 RR024999 (TG), CA 27469 and CA 37517 (GOG AO and SDC) and EIF NWCRA (OIO)
cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes
Authors: Mulin Jun Li, Miaoxin Li, Zipeng Liu, Bin Yan, Zhicheng Pan, Dandan Huang, Qian Liang, Dingge Ying, Feng Xu, Hongcheng Yao, Panwen Wang, Jean-Pierre A. Kocher, Zhengyuan Xia, Pak Chung Sham, Jun S. Liu, Junwen Wang
Journal: Genome biology (2017)

It remains challenging to predict regulatory variants in particular tissues or cell types due to highly context-specific gene regulation. By connecting large-scale epigenomic profiles to expression quantitative trait loci (eQTLs) in a wide range of human tissues/cell types, we identify critical chromatin features that predict variant regulatory potential. We present cepip, a joint likelihood framework, for estimating a variant's regulatory probability in a context-dependent manner. Our method exhibits significant GWAS signal enrichment and is superior to existing cell type-specific methods. Furthermore, using phenotypically relevant epigenomes to weight the GWAS single-nucleotide polymorphisms, we improve the statistical power of the gene-based association test.
Correlation between development of rash and efficacy of EGFR inhibitors: A meta-regression analysis.
Authors: Camilo A. Ortega-Parra, Elie Donath, Salvador Ricardo Garcia, Robert J. Jacobson
Journal: Journal of Clinical Oncology (2013)

e13539 Background: Treatment with Epidermal Growth Factor (EGFR) inhibitors is frequently characterized by the presence of a rash. Previous research has suggested that developing this rash may be associated with improved outcomes. It has been difficult, however, to establish a direct link between occurrence of a rash and tumor response. Rashes are also likely to occur with greater drug exposure and it is possible that they exist as a confounder in the well established relationship between drug exposure/dosing and tumor response. The purpose of this meta-regression analysis is to define whether a correlation exists between the incidence of rash and clinical outcomes including response rate (RR), progression-free survival (PFS) and overall survival (OS) and then examine whether a similar relationship exists with other adverse events as that would suggest that rash occurrence is simply a function of drug dosing and not necessarily an indicator of tumor response. Methods: A literature search for RCT’s involving EGFR inhibitors in non-small cell lung cancer (NSCLC) identified 31 trials. This included 5 trials of Cetuximab, 13 trials of Gefitinib and 13 trials of Erlotinib. Multivariate meta-regression analysis was performed to evaluate whether all rashes (grades 1-5) and severe rashes (grades 3-5) as well as vomiting and neutropenia (two randomly chosen adverse events) may have influenced effect size (measured by RR, PFS and OS) across this cancer type. Results: The presence of severe rashes in the treatment arm was positively correlated with increased PFS (p&lt;0.01) in NSCLC - a similar correlation was also found for risk of vomiting. Additionally, the presence of any rash in the treatment arm was positively correlated with increased OS (p=0.03) in NSCLC – a similar correlation was found for risk of vomiting and neutropenia. Conclusions: The presence of a rash seems to connote an increased likelihood of tumor response and/or survival in NSCLC. The fact that other adverse events (vomiting and neutropenia) are more evident in these responding patients suggests that rash occurrence may simply be a confounder in the EGFR inhibitors’ dose-response relationship as opposed to being independently associated with any tumor response.
ASSOCIATION OF 10-YEAR CHANGE IN CARDIOVASCULAR RISK FACTORS WITH PROGRESSION OF PERICARDIAL ADIPOSE TISSUE: THE CARDIA STUDY
Authors: Lane Benes, James Terry, John Carr, David Jacobs, David Goff, Joseph Yeboah, Amy C. Alman, Jamal Rana, Cheeling Chan, Kiang Liu, Tamar Polonsky
Journal: Journal of the American College of Cardiology (2017)
Hypocalcemia in patients with metastatic bone disease receiving denosumab.
Authors: Jean-Jacques Body, Allan Lipton, David H. Henry, Alison Stopeck, Karim Fizazi, Henry G. Bone, Fred Saad, Catherine H. Van Poznak, Richard H. De Boer, Neal D. Shore, Toni Ibrahim, Toshimi Takano, Ronaldo Damião, Huei Wang, Paul J. Kostenuik, Adam Shaywitz, Oswaldo L. Bracco, Ada Braun
Journal: Journal of Clinical Oncology (2013)

9628 Background: Patients (pts) with metastatic bone disease (MBD) are at risk of skeletal-related events (SREs). Potent antiresorptives reduce the risk of SREs, by inhibiting cancer-induced bone destruction, which also reduces release of skeletal calcium (Ca) into the bloodstream. Hypocalcemia (hypoCa) may occur if Ca and vit D intake is inadequate while taking antiresorptive agents. A combined analysis of 3 phase III trials in pts with MBD showed denosumab (DMAb) was superior to zoledronic acid (ZA) in preventing SREs. The overall safety profiles were similar; hypoCa was more common with DMAb (9.6%) than ZA (5.0%). Characteristics of hypoCa events in DMAb pts in these clinical trials and from post marketing adverse event (AE) reports are presented. Methods: Pts with solid tumors or multiple myeloma and MBD were randomized (1:1) to DMAb 120 mg SC or ZA 4 mg IV (adjusted for renal function) every 4 weeks (Q4W). Pts were advised to take daily Ca (≥ 500 mg) and vit D (≥ 400 IU); intake was collected by pt report. Albumin-corrected serum Ca was measured Q4W by central lab. HypoCa events were collected as decreases in serum Ca per central lab and investigator-reported AEs. Post marketing data from spontaneous reports of hypoCa to the sponsor's global safety department (AGS) were reviewed. Results: In the 3 trials, 2841 pts received DMAb and 2836 pts received ZA. The median Ca levels for both treatment groups were similar over time. Among DMAb pts, hypoCa was most common within 6 months of starting treatment and was more common in pts who did not report use of Ca and vit D vs those who did (15.8% vs 8.7%). Grade 3 or 4 (&lt; 7 mg/dL; &lt; 1.75 mmol/L) decreases in serum Ca were reported in 3.1% of DMAb pts and 1.3% of ZA pts. No fatal cases of hypoCa were reported in the trials. From May to Nov 2012, 37 cases of severe symptomatic hypoCa (seizures, tetany, prolonged QTc, altered mental state) were reported to AGS; fatal outcomes were reported for 3 other pts with advanced cancers and various comorbidities. Conclusions: HypoCa is a known risk with antiresorptive therapy, including DMAb 120 mg. HypoCa occurred less often in pts who reported taking Ca and vit D. HypoCa should be corrected prior to starting DMAb and Ca monitored during treatment. Pts should take adequate Ca and vit D while receiving DMAb. Clinical trial information: NCT00321464, NCT00321620, and NCT00330759.
HER2 gene status assessment in micrometastatic cells in bone marrow (BM) of breast cancer patients by fluorescence in situ hybridization (FISH)
Authors: A. Vincent-Salomon, J. Couturier, C. Nos, X. Sastre-Garau, P. Pouillart, H. Magdelénat, J. P. Thiery, B. Sigal-Zafrani, J. Y. Pierga
Journal: Journal of Clinical Oncology (2004)

9520 Background: Detection of micrometastatic cells in BM of breast cancer patients has been shown to be an independent prognostic factor. HER2 overexpression occurs in 15% to 30% of breast cancers. HER2 overexpression on micrometastatic cells has been reported in 60% of the patients, independently of primary tumor status (Braun, S. Cancer Res., 61, 2001, 1890). In metastatic breast cancer patients, a rate of 100% of HER2 positive micrometastatic cells has been reported (Pantel, K., JNCI, 85, 1993, 1419). These results were obtained by immunocytochemical double labeling techniques with anti-cytokeratin and HER2 antibodies. The aim of this study was to assess HER2 status in micrometastatic cells in BM of breast cancer patients by FISH and to compare it to primary tumor status. Methods: Disseminated micrometastatic cells were detected in BM aspirations from breast cancer patients in a prospective series. The pancytokeratin (CK) monoclonal antibody A45-B/B3 was used and CK+ cells were detected by an automated cellular imaging system (ACIS) (ChromaVision Medical System). Positive samples of BM for micrometastatic cells (CK+) detection and their corresponding primary tumors, were obtained from 27 patients (3 stage II, 1 stage III and 23 stage IV). HER2 status of micrometastatic cells in BM was assessed by FISH. HER2 status of primary tumor was assessed by immunohistochemistry (CB11 antibody) and confirmed by FISH in ++ cases. Results: 5/27 (18.5%) patients had HER2 overexpression in primary tumors and 4/27 (15%) (CI 95%: 2–28%) had HER2 amplification in micrometastatic cells in BM. Concordance rate between primary tumor and bone marrow status was 90%. In 2 cases HER2 was overexpressed in primary and not in distant BM cells and in one case, HER2 was amplified in BM tumoral cells (6 copies) and not in primary. In four additional cases, chromosome 17 trisomy was detected in BM micrometastatic cells without amplification of HER2. Conclusions: The HER2 status assessed by FISH in metastatic isolated BM cancer cells is highly correlated with primary tumor status. Our study confirmed the stable status of HER2 during the metastatic process. No significant financial relationships to disclose.
SARCOPENIA AND VASCULAR FUNCTION AMONG COMMUNITY ELDERLY
Authors: Angela Su-Mei Koh, Jia Ing Wong, Wan Yi Yew, Serene J.M. Chua, Feiqiong Huang, Shuang Leng, Liang Zhong, Si Yi Lee, Fei Gao, Ru-San Tan, Woon-Puay Koh
Journal: Journal of the American College of Cardiology (2017)
Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer (NSCLC) patients (pts) treated with first-line chemotherapy.
Authors: Anna K. Brady, Jonathan D McNeill, Brendan Judy, Tracey L. Evans, Roger B. Cohen, Corey J. Langer, Anil Vachani, Charu Aggarwal
Journal: Journal of Clinical Oncology (2012)

7595 Background: KRAS mutations (MT) form a distinct subset of NSCLC, generally considered to have poor prognosis. Although KRAS MT is a well-establised prognostic and predictive marker in colorectal cancer, its role in NSCLC remains ambiguous. Pts with KRAS MT NSCLC do not respond well to epidermal growth factor receptor (EGFR) directed tyrosine kinase inhibitor therapy, but little is known about the ability of KRAS MT to predict outcome after first-line chemotherapy in newly diagnosed advanced or recurrent NSCLC. Methods: We analyzed outcomes of consecutive pts with newly identified Stage IV non- squamous NSCLC treated at University of Pennsylvania (Penn) between 05/2008 and 7/2010 and then compared survival based on KRAS status [MT vs wild type (WT)] using chi square, Kaplan-Meier methods, and Cox regression models. Results: Of 106 consecutive new pts with Stage IV non squamous NSCLC treated at Penn, 49 (46%) underwent molecular analysis for KRAS MT. Fifteen (34%) were KRAS MT. Of 34 KRAS WT pts, 6 were positive for EGFR MT. The median age of all 49 pts was 61 years; 83% were Caucasian, 45% male and 60% had a &gt;10 pack year smoking history. Median duration of follow up is 16.4 mos. Majority of pts (92%) had adenocarcinoma histology. Most pts (88%) had ECOG PS 0-1 at presentation. Forty three pts received first line platinum-based combination chemotherapy (platinum and pemetrexed in 31 pts). KRAS MT was associated with smoking (p=0.04), but not with gender or age. Overall survival (OS) of pts with KRAS MT was similar to KRAS WT pts [median OS 15.6 vs. 19.0 mos; HR 1.24 (95% CI 0.57-2.67)]. Univariate analyses demonstrated superior OS among women compared to men (HR 0.40, 95% CI 0.20-0.85) in the entire pt cohort. Conclusions: In our population of stage IV non squamous NSCLC, pts with KRAS MT had similar OS to those with KRAS WT tumors. OS was slightly higher in KRAS WT pts, but this may have been confounded by the inclusion of 6 EGFR MT pts in this cohort. The potential prognostic or predictive role of KRAS MT in NSCLC pts undergoing chemotherapy requires further prospective study.
Utility of FDG-PET and Comparison of FDG-PET and Ga-67 Scintigraphy in Evaluation of B-Cell Indolent Lymphoma.
Authors: Norifumi Tsukamoto, Akihiko Yokohama, Hiroyuki Irisawa, Takayuki Saitoh, Hideki Uchiumi, Takafumi Matsushima, Yoshihisa Nojima, Masamitsu Karasawa, Hiroshi Handa, Hirokazu Murakami
Journal: Blood (2006)
TEMPORAL TREND OF INCIDENCE OF STENT THROMBOSIS AND IN-HOSPITAL MORTALITY: RESULTS FROM A NATIONAL REAL-WORLD REGISTRY
Authors: Gaurav Patel, Maitri Pancholy, Sukrut Nanavaty, Neha Pancholy, Aman Patel, Anvit Rai, Mark Sandhaus, Tejas Patel, John Coppola, Tak Kwan, Samir Pancholy
Journal: Journal of the American College of Cardiology (2017)
TRANSMURAL MACROPHAGE MIGRATION IN TISSUE ENGINEERED VASCULAR GRAFT PROMOTES EXTRACELLULAR MATRIX FORMATION FOR VASCULAR REMODELING MORE THAN HOST CIRCULATING INFLAMMATORY CELL MIGRATION
Authors: Hideki Miyachi, Shuhei Tara, Tadahisa Sugiura, Tai Yi, Yong-Ung Lee, Avion Y. Lee, Shinka Miyamoto, Toshihiro Shoji, Christopher K. Breuer, Toshiharu Shinoka
Journal: Journal of the American College of Cardiology (2017)
Immunohistochemical validation of novel candidate biomarkers for colorectal cancer.
Authors: Cleberson Jean dos Santos Queiroz, Lenuce Ribeiro Aziz Ydy, Fabio Miyajima, John Jenkins
Journal: Journal of Clinical Oncology (2015)

e22251 Background: Colorectal cancer (CRC) is the 3rd most common form of malignancy worldwide. Our group has used proteomic dissection of a model of CRC (AhCre+Apcfl/fl mouse) to identify potential biomarkers. Here, we present the preliminary validation analysis of NAP1L1, RPL6, Prohibitin (PHB) and HMGB1 in human CRC. Methods: We carried out immunohistochemical analysis of FFPE samples from CRC patients; we assessed the expression of the proteins both in tumours (early vs late stages) and in normal mucosa. Stained sections were scored for cytoplasmic (modified H-score) and nuclear (% of positive nuclei) expression. The results (continuous data) were compared using ANOVA and Tukey’s test. Results: Thirty-four patients were included. Beta-catenin showed stronger nuclear and cytoplasmic staining in cancer compared to the adjacent mucosa, confirming the activation of Wnt pathway. NAP1L1 was decreased in cancer tissues, especially in the nuclei. The same trend was observed with RPL6 nuclear expression. PHB exhibited a decrease in the nuclear staining along with an increase in the cytoplasm. No difference was observed with HMGB1 nor when comparing early vs late stages. Conclusions: Our Beta-catenin analysis is in agreement with previous studies. RPL6 and PHB exhibited significant, albeit minor in magnitude, changes in the nuclear/cytoplasmic balance, whereas, NAP1L1 showed a much more noticeable and significant change, which could be potentially useful for diagnostic/prognostic purposes. Mean expression of the biomarkers in normal vs cancer tissues (± SD). Normal Cancer (stage I-II) Cancer (stage III-IV) Beta-catenin nuclear cytoplasmic 24.2 (±14.2) 98.2 (±32.5) 55.7 (±31.1)*** 138.0 (±65.5)** 54.6 (±29.4)*** 146.2(±60.8)** NAP1L1 nuclear cytoplasmic 53.2 (±16.7) 139.8 (±41.8) 24.9 (±20.0)*** 101.3 (±43.8)** 28.6 (±20.1)*** 94.8 (±43.3)** RPL6 nuclear cytoplasmic 66.4 (±16.0) 138.8 (±46.9) 53.6 (±24.5)* 138.1 (±41.8) 49.0 (±22.5)* 144.2 (±50.0) PHB nuclear cytoplasmic 82.3 (±7.0) 133.3 (±44.4) 62.8 (±12.2)*** 166.8 (±30.7)** 66.1 (±17.4)*** 179.9 (±39.0)** HMGB1 nuclear cytoplasmic 69.7 (±19.7) 145.8 (±42.7) 77.4 (±18.4) 142.9 (±32.6) 72.5 (±14.3) 160.3 (±40.8) * p<0.05; ** p<0.01; ***p<0.001 (normal vs cancer).
ENTROPY OF FIBRILLATORY WAVES CONTRIBUTES TO DIFFERENTIATING PAROXYSMAL FROM PERSISTENT AND PERMANENT ATRIAL FIBRILLATION
Authors: Sungsoo Kim, Sohee Kwon, Ira Blau, Hye Jin Hwang, Junbeom Park, Moon-Hyoung Lee, Lindsey Krawchuk, Nicholas Meyers, Byung-Il Choi
Journal: Journal of the American College of Cardiology (2017)
Randomized phase II study of biweekly gemcitabine (gem)-paclitaxel (pac), gem-carboplatin (carb) and gem-cisplatin (cis) as first-line treatments in metastatic breast cancer (MBC) after anthracycline failure
Authors: B. Xu, Z. Jiang, S. Kim, S. Yu, J. Feng, A. Malzyner, A. Del Giglio, H. Chung, M. Yu, A. Serrano
Journal: Journal of Clinical Oncology (2007)

1099 Background: Biweekly gem-pac and gem-cis regimens have shown promising activity and safety in different tumor types. In MBC biweekly gem-pac is active and well tolerated. The aim of this multi-country study is to evaluate the efficacy and safety of gem in combination with pac, carb or cis on a biweekly schedule in patients (pts) with MBC. Methods: Major eligibility criteria included: tissue diagnosis of stage IV breast carcinoma; prior anthracycline therapy; ECOG performance status (PS) of 0 or 1; and written informed consent. Pts were randomized to receive gem 2500 mg/m 2 in combination with pac 150 mg/m 2 (Arm A), carb AUC 2.5 (Arm B) or cis 50 mg/m 2 (Arm C) on day 1 of 2-week cycles. The primary endpoint was response rate, with safety a secondary endpoint. Results: This interim analysis was planned to occur when patient enrollment had reached 50% (75/150 pts), at which point there were 26 pts in Arm A, 25 in Arm B and 24 in Arm C, with 12 pts still on treatment. The baseline characteristics were similar in the three arms, including mean age (Arm A 50.2 yr, Arm B 46.1, Arm C 47.3); ECOG PS (PS 0: 50.0%, 64.0%, 54.2%); mean number of sites of tumor involvement (2.9, 2.6, 2.7); dominant type of metastasis (visceral: 73.1%, 80.0%, 79.2%); and disease-free interval (&lt;24 mo: 53.8%, 60.0%, 41.7%). The mean number of cycles was 6.4, 6.0 and 5.8. There was a partial response in 5/26 efficacy qualified pts (19.2%), 5/25 pts (20.0%) and 2/23 pts (8.7%) in Arms A, B and C, respectively, stable disease in 10 pts (38.5%), 9 pts (36.0%) and 9 pts (39.1%), and progressive disease in 5 pts (19.2%), 6 pts (24.0%) and 6 pts (26.1%). There were no treatment-related deaths. Conclusions: The three regimens appear to show activity and have manageable toxicity when given on a biweekly schedule. [Table: see text] No significant financial relationships to disclose.
Survival after Relapse Following Tandem Allogeneic Vs. Tandem Autologous Hematopoietic Cell Transplantation (HCT) for Myeloma (MM)
Authors: Myo Htut, Anita D'Souza, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Cristina Gasparetto, Yago Nieto, Amrita Krishnan, Parmeswaran Hari
Journal: Blood (2016)
Thalidomide shows activity in patients with heavily pretreated germ-cell tumors
Authors: O. Rick, J. Beyer, T. Braun, U. Marquart, W. Siegert
Journal: Journal of Clinical Oncology (2004)

4722 Background: To assess the activity of thalidomide in patients (pts.) with germ-cell tumors (GCT) and progressive inoperable disease after salvage chemotherapy. Methods: Between April 2002 and January 2003, 15 pts were included in a phase I/II study and treated with escalated daily doses of 200 to 600 mg of thalidomide. All pts had relapsed or progressed after salvage treatment and were considered inoperable. Pts had received a median of six (range, 4 to 12) cisplatin-based treatment cycles. Before study treatment 13/15 (87%) pts had received high-dose chemotherapy (HDCT), 3/15 pts (20%) were considered refractory and 5/15 (33%) pts absolute refractory to cisplatin. Oral etoposide, gemcitabine plus oxaliplatin, combinations of paclitaxel, ifosfamide and cisplatin or other palliative treatments had been tried in 8/15 (53%) pts prior to thalidomide administration. Results: Overall, 5/15 (33%) pts achieved a marker-positive partial remission (33%) and one additional patient achieved disease stabilization. The median duration of remission was 3 months (range of 2 to 12 months). Responses to thalidomide were independent from tumor mass, platinum-sensitivity or the degree of tumor marker elevations. However, responses were almost exclusively seen in pts with slowly increasing alpha-fetoprotein (AFP). Toxicity was mild, with lethargy and constipation in the majority of pts. Skin rash CTC grade II° developed in two pts and neurotoxicity CTC grade II/III° developed in four pts. One responding patient died suddenly from an unknown cause. Conclusions: Thalidomide shows single-agent activity in pts with heavily pretreated GCT, AFP elevations and slowly progressive disease. No significant financial relationships to disclose.
PREDICTORS OF NEW PERSISTENT LEFT BUNDLE BRANCH BLOCK AFTER EDWARDS SAPIEN 3 TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Mohammed Hasan Khan, Sahil Khera, Samuel Schnittman, Audrey Love, Areeb Shareef, Amole Ojo, Hasan Ahmad, Ryan Kaple, Cenap Undemir, Martin Cohen, Joanne Bennett, Tanya Dutta, Anthony Gilet, Anna Rozenshtein, Angelica Poniros, Alexis Kearns, Cheng Feng, Steven Lansman, Gilbert Tang
Journal: Journal of the American College of Cardiology (2017)